OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Drug Metabolism & Toxicology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Probing the mechanism of reduced in vivo potency of insulin detemir	130
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata	92
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects	47
Comorbidities and the right dose: antipsychotics	47
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database	38
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas	36
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury	35
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria	31
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine	24
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury	24
Hormones, microbes, and PrEP drugs in the female genital tract	23
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis	22
Guidance for interactions between antiseizure medications	21
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis	20
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update	20
Bioactivity descriptors for in vivo toxicity prediction: now and the future	19
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study	19
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease	17
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update	17
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer	17
A comprehensive review of the efficacy and safety of ertugliflozin	16
Correction	16
Pharmacokinetic evaluation of concizumab for the treatment of hemophilia	15
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury	15
Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase	14

In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals	14
A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition	13
Pharmacokinetic considerations surrounding triple therapy for uncontrolled asthma	13
Physiologically based pharmacokinetic modeling in obesity: applications and challenges	13
Development and hepatotoxicity of rifamycin derivatives	13
A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of p -cresol sulfate, p -cresol	13
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview	13
Clinical pharmacokinetics and pharmacodynamics of nicardipine; a systematic review	13
Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen	13
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders	13
Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase	13
The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity – a review of pharmacological and clinical data	12
Drug-drug interactions between psychotropic medications and oral contraceptives	12
Evaluating pharmacokinetic drug–drug interactions of direct oral anticoagulants in patients with renal dysfunction	12
Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia	12
Risk factors and prediction for DILI in clinical practice	12
Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature	11
The impact of advanced age on anticoagulant therapy for acute venous thromboembolism	11
Integrative approaches for studying the role of noncoding RNAs in influencing drug efficacy and toxicity	11
Recent progress in machine learning approaches for predicting carcinogenicity in drug development	11
CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study	11
Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review	11
Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation	11
Current state-of-the-art approaches for mass spectrometry in clinical toxicology: an overview	11
Population pharmacokinetic–pharmacodynamic analysis of givinostat	11
Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study	10
Practical perspectives on addressing hepatotoxicity during clinical candidate selection	10
PBPK models of the female reproductive tract: current and future analysis	10
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes	10
Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction	10
Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants	10
Interactions between phytotherapeutics and chemotherapeutics: the current evidence	10
In-silico approaches to assessing multiple high-level drug-drug and drug-disease adverse drug effects	10
An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease	9
Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease	9
Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers	9
Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies	9
Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling	9
Lessons learned from aldehyde dehydrogenases as non-P450 aldehyde-oxidizing enzymes: implications for the ‘exposome’ and human health	9
Overcoming barriers to machine learning applications in toxicity prediction	9
Analysis of drug–drug interactions in patients with HIV and metabolic syndrome	9
Positioning the new drugs for migraine	9
Cardiomyocyte-specific CYP2J2 and its therapeutic implications	9
Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults	9
Pharmacokinetics of apixaban in patients with short bowel syndrome: a Bayesian re-estimation approach	8
Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention	8
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications	8
Drug interactions in people with HIV treated with antivirals for other viral illnesses	8
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis	8
Pharmacokinetic and pharmacodynamic alterations in older people: what we know so far	8

Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids	8
Switching from cangrelor to oral P2Y ₁₂ inhibitors: a focused review on drug–drug interactions	8
The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications	8
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healt	8
Machine learning and deep learning approaches for enhanced prediction of hERG blockade: a comprehensive QSAR modeling study	8
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review	7
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability	7
Drug–drug interactions in HIV-infected patients receiving chemotherapy	7
Considerations for drug–drug interactions between long-acting antiretrovirals and immunosuppressants for solid organ transplantation	7
DILI prediction in drug development: present and future	7
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study	7
Mechanism-based drug safety testing using innovative in vitro liver models: from DILI prediction to idiosyncratic DILI liability assessment	7
Drug dosing optimization in critically ill children under continuous renal replacement therapy: from basic concepts to the bedside model informed precision dosing	7
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine	7
Psychedelics, psychiatry and pharmacokinetics - where are we now?	7
Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBα modifiers	7
Interindividual variability in statin pharmacokinetics and effects of drug transporters	7
Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxi	7
Toxic metabolites and metabolic soft spots of celastrol based on glutathione metabolic capture and high-resolution mass spectrometry	7
Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage	7
Managing intoxications with nicotine-containing e-liquids	7
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout	7
Pharmacokinetic studies in dialysis-dependent patients: limited data availability	7
A comparative study on the consistency of different decision support software systems from the perspective of potential drug–drug interactions in intensive care unit patients	7